Key result
Trimetazidine and CoQ10 target shared pathways to potentially counter antipsychotic-induced myocarditis.
Why the study?
Antipsychotic-induced myocarditis is a potentially fatal adverse event, and the molecular mechanisms and therapeutic relevance of cardioprotective trimetazidine and coenzyme Q10 remain unclear.
Computational network pharmacology and molecular dynamics simulations provide theoretical evidence that trimetazidine and coenzyme Q10 may protect against antipsychotic-induced myocarditis by targeting the PI3K/AKT signaling pathway and core proteins such as STAT3 and MMP9.
Answers are grounded in this paper and cite their sources.
No immediate clinical role; leaves open whether trimetazidine or CoQ10 prevent antipsychotic-induced myocarditis.
BACKGROUND: Antipsychotic-induced myocarditis is a rare but potentially fatal adverse event associated with antipsychotic treatment. Trimetazidine (TMZ) and coenzyme Q10 (CoQ10) have shown potential cardioprotective effects. Thus, they may represent adjunctive therapeutic candidates for antipsychotic-induced myocarditis. However, the underlying molecular mechanisms and therapeutic relevance of this remain unclear. This study aimed to identify the potential pharmacological mechanisms and therapeutic targets of TMZ and CoQ10 in antipsychotic-induced myocarditis. METHODS: Drug- and disease-associated targets were retrieved or predicted using SwissTargetPrediction, SEA, PharmMapper, Super-PRED, and GeneCards. Overlapping drug-disease targets were identified and used to construct a protein-protein interaction network and determine the core targets. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were then performed using DAVID. Finally, molecular docking and molecular dynamics simulations were conducted to evaluate ligand-target interactions and the stability of the selected complexes. RESULTS: Twenty-six overlapping TMZ-disease targets and 27 overlapping CoQ10-disease targets were identified. GO and KEGG enrichment analyses revealed that these targets were involved in multiple biological processes, cellular components, molecular functions, and signaling pathways. Thirty-nine unique drug-disease intersection targets were obtained after merging the TMZ-disease and CoQ10-disease targets and five core targets were identified: STAT3, NFKB1, HIF1A, CASP3, and MMP9. Further GO and KEGG enrichment analyses were conducted for the 39 drug-disease intersection targets. GO enrichment analysis indicated that the apoptotic process was greatly enriched, whereas KEGG analysis highlighted the PI3K/AKT signaling pathway. Molecular docking suggested that TMZ and CoQ10 could form stable interactions with the core targets, supporting their potential therapeutic relevance. The molecular dynamics simulations further supported the stability of the selected ligand-target complexes. CONCLUSIONS: Network pharmacology, molecular docking, and molecular dynamics simulations were used to investigate the potential pharmacological mechanisms underlying the effects of TMZ and CoQ10 in antipsychotic-induced myocarditis. The findings provide theoretical and computational evidence for future experimental studies on TMZ and CoQ10 as potential adjunctive therapeutic candidates for antipsychotic-induced myocarditis.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied Antipsychotic-induced myocarditis. Trimetazidine and Coenzyme Q10 was evaluated on Core targets and binding stability. Trimetazidine and Coenzyme Q10 stably bind to core targets STAT3, NFKB1, HIF1A, CASP3, and MMP9, suggesting potential mechanisms against antipsychotic-induced myocarditis via the PI3K/AKT pathway.
Synapse has enriched 5 related papers. Consider them for comparative context: